

Form PTO-1449 (modified)	Atty. Docket No.: CLFR:009US	Serial No.: 09/992,556
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant: Jordan U. GUTTERMAN Valsala HARIDAS	
	Filing Date: November 16, 2001	Group: 1612
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-2

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B12	WO 99/65495	12/23/99	WIPO	English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C133	Anisimov <i>et al.</i> , "Comparative study of cytotoxic activity of triterpene glycosides from marine organisms," <i>Toxicon.</i> , 18:221-223, 1980.
	C134	Anisimov <i>et al.</i> , "Mechanism of cytotoxic action of some triterpene glycosides," <i>Toxicon.</i> , 16:207-218, 1978.
	C135	Barnes, "Nuclear factor-kappa," <i>Int. J. Biochem. Cell. Biol.</i> , 29(6):867-70, 1997.
	C136	Fujioka <i>et al.</i> , "Antitumor Agents. 168 <sup>1)</sup> <i>Dysoxylum cumingianum.</i> , IV. <sup>2)</sup> The structures of Cumingianosides G-O, new triterpene glucosides with a 14,18-cycloapotirucallane-type skeleton from <i>Dysoxylum cumingianum</i> , and their cytotoxicity against human cancer cell lines," <i>Chem. Pharm. Bull.</i> , 45(1):68-74, 1997.
	C137	Handel <i>et al.</i> , "Inhibition of transcription factors by anti-inflammatory and anti-rheumatic drugs: can variability in response be overcome?" <i>Clin Exp. Pharmacol. Physiol.</i> , 27(3):134-44, 2000.
	C138	Office Communication, issued in Canadian Patent Application No. 2,429,177, dated May 11, 2009.
	C139	Office Communication, issued in European Patent Application No. 01 993 164.1, dated June 10, 2009.
	C140	Riehemann <i>et al.</i> , "Plant extracts from stinging nettle ( <i>Urtica dioica</i> ), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF- $\kappa$ B," <i>FEBS Letters</i> , 442(1):89-94, 1999.

55428078.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.W./

Form PTO-1449 (modified)	Atty. Docket No.: CLFR:009US	Serial No.: 09/992,556
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant: Jordan U. GUTTERMAN Valsala HARIDAS	
	Filing Date: November 16, 2001	Group: 1612
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-2

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C141	Schreiber <i>et al.</i> , "Activation of nuclear factor $\kappa$ B inflammatory bowel disease," <i>Gut</i> , 42(4):477-484, 1998.
	C142	Thiele <i>et al.</i> , "Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease," <i>Gut</i> , 45(5):693-704, 1999.

55428078.1

EXAMINER: /Walter Webb/	DATE CONSIDERED: 03/09/2010
-------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.W./